AcceleDev is a small molecule development & production company, with a staff of 100 people. Global operations include R&D & manufacturing sites in USA & China. Business specialties in the areas of "custom synthesis of advances intermediates" & "qualification/supply of raw materials", primarily in support of Pharmaceutical API programs.
MINAKEM is a fully integrated development partner and commercial manufacturer for pharmaceutical companies.
- API manufacturing (Innovators/Generics and Highly Potent)
- Custom development (process development and optimization)
- Custom manufacturing
- Production of Key intermediates and building blocks
All development and manufacturing activities are supported by highly skilled R&D technical centres, strong and state of the art analytical services including solid form and QBD laboratories.
MINAKEM’s talented team also ensures high-quality services in Quality Assurance, Regulatory Affairs, Safety, Health and Environment (SHE).
Minakem is a technology-driven company with expertise in complex multi-step synthesis, pressure chemistry, chiral synthesis, halogenation chemistry, steroid chemistry and “prazole” chemistry…
Minakem has operations in 3 different sites, which are all US FDA and local health agencies approved and is :
- Dunkirk, France – former AstraZeneca “prazoles” and budesonide production site
- Beuvry-la-Forêt, France
- Louvain-la-Neuve, Belgium – former Ajimonoto-Omnichem site, specialized in vinca alkaloids synthesis
Strong synergies within MINAKEM facilities sites offer customers the flexibility, responsiveness and cost-effectiveness paired with the strong technical know-how to create significant added value within our customers’ supply chains.
Minakem is part of the Minafin Group (link to Minafin site), and as such has access to all technologies, resources, and capabilities to respond to its client’s needs, especially with Leuna, Germany, and Pennakem (USA).
Own products (APIs) for the generic pharmaceutical industry.
We provide quality products and services, consistently,
reliably responsibly and continuously applying some of the world’s
most difficult to handle chemical technologies.
Our independent one-site,
single entity corporate setup enables
Synthesis: Manufacturing services and products for all user industries,
using Archimica´s highly differentiated setup and technologies
APIs, Building blocks, GMP intermediates, Regulatory Starting Materials
For all global markets including the United States of America,
in total Archimica products reach 25 countries.
Avra Labs was established in the year 1995 and is among the first in India to focus on providing high-end contract research and manufacturing of advanced intermediates and APIs covering oncology and other therapeutic areas. Today, with our strong team of 600+ employees, we are focused on providing custom synthesis solutions across the value chain, right from developing a cost-effective process to supplying commercial quantities from our facilities, which include USFDA and GMP approved sites.
Being founded by one of India's most distinguished scientists, Dr. A. V. Rama Rao (https://en.wikipedia.org/wiki/A._V._Rama_Rao), we take pride in our cutting edge chemistry capabilities. We are the only company in the world to develop and successfully commercialize a synthetic process for Irinotecan, and have partnered with some of the largest global innovators to develop advanced intermediates and supply them at a commercial scale post-launch.
Our state-of-the-art manufacturing facilities are spread over 30 acres with a total reactor volume over 165.000 liters, located in Hyderabad (USFDA approved) and Vizag.
Please visit our website for more information (www.avralab.com) and reach out to us at firstname.lastname@example.org for anything you may need.
DOTTIKON ES manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical, biotech, and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. Its safety culture created over the past 105 years guides the innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing in order to challenge, tighten, or shorten conventional chemical synthesis routes, improve selectivities, yields, and purities, and reduce waste.
The versatile technology and equipment portfolio is used, maintained, and continuously expanded to design, develop, and optimize chemical processes and technical manufacturing procedures for the rapid scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.
DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development, clear and transparent data and process documentation, and close customer communication.